On the outskirts of Boston, there was a research institute that covered more than 100 acres.
This research institute was originally a collaborative unit with the Massachusetts Institute of Technology, controlled by a pharmaceutical company with a market cap of approximately US$2 billion.
Its research was mainly focused on clinical biology.
However, after it was acquired by the Boston Financial Group, they began to pivot. Their research became focused on human cryonics technology. Their funding came from a well-known cancer charity, which gave them a billion USD of funding. Their aim was to send terminally-ill patients into the future, where they had a higher chance of being cured.
This cryobiology research institute was now managed by Space-X, merging with Space-X's frozen dormancy laboratory.
